Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple Sclerosis Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

NCT03723356
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Siemens Biograph mMR (molecular MR), fMRI, Diffusion Spectrum Imaging (DSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 8, 2026, 11:23 PM EDT
Not listed Phase 4 Interventional

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

NCT04048577
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Dosing Interruption of Natalizumab
Drug
Lead sponsor
Berkovich, Regina MD, PhD Inc.
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 8, 2026, 11:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557
View directory record Official record
Conditions
Secondary-progressive Multiple Sclerosis
Interventions
Mayzent, Ocrevus
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 8, 2026, 11:23 PM EDT
Completed No phase listed Observational

A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients

NCT07566988
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Proximal Resistance Training for People With Multiple Sclerosis

NCT04548154
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Proximal Resistance Training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 8, 2026, 11:23 PM EDT
Completed No phase listed Observational

Functional Intermuscular Reduction of Spasticity

NCT04403594
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dry needling
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

NCT01848327
View directory record Official record
Conditions
Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions
Caprylic Triglyceride, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 8, 2026, 11:23 PM EDT
Recruiting No phase listed Observational

Ocrevus Zunovo for MS: Mixed Methods

NCT07710105
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Clinical Questionnaires, Semi-Structured Interviews, Ocrevus Zunovo
Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 8, 2026, 11:23 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis

NCT04415372
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
MRI, Neuropsychological Testing
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional

Aerobic Exercise for Remyelination in Multiple Sclerosis

NCT04539002
View directory record Official record
Conditions
Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Autoimmune Diseases, CNS, Exercise
Interventions
Aerobic exercise, Education Group Control
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Effects of Acthar on Recovery From Cognitive Relapses in MS

NCT02290444
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 8, 2026, 11:23 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients

NCT03092544
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

NCT00475865
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide), Glatiramer Acetate (GA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Intervention Responsiveness in People With Multiple Sclerosis

NCT01632293
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
progressive resistance training
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
21 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 8, 2026, 11:23 PM EDT
Recruiting Not applicable Interventional

Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS

NCT05500963
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Transcutaneous electrical nerve stimulation
Device
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Multimodal Exercise Training to Reduce Frailty in People With Multiple Sclerosis

NCT06042244
View directory record Official record
Conditions
Multiple Sclerosis, Frailty
Interventions
Multimodal Exercise Group, Waitlist
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 8, 2026, 11:23 PM EDT
Terminated Not applicable Interventional

Exercise and Learning and Memory in Multiple Sclerosis

NCT03319771
View directory record Official record
Conditions
Multiple Sclerosis, Physical Activity, Memory Impairment, Cognitive Change
Interventions
Treadmill Walking Exercise Training, Stretching-and-toning Exercise Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 54 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 8, 2026, 11:23 PM EDT
Terminated Phase 3 Interventional Results available

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

NCT01633112
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions
fingolimod, glatiramer acetate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
101
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis

NCT01024777
View directory record Official record
Conditions
Multiple Sclerosis, Vitamin D Deficiency
Interventions
Cholecalciferol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Sep 8, 2026, 11:23 PM EDT
Completed No phase listed Observational

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

NCT02907281
View directory record Official record
Conditions
Multiple Sclerosis, RRMS
Interventions
Observational
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
San Francisco, California • Torrance, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 8, 2026, 11:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Effects of Immunomodulatory Drugs in MS

NCT00229502
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Sharon Lynch, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2012 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
38
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 8, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 8, 2026, 11:23 PM EDT